Natco Pharma’s wholly-owned Canadian subsidiary, Natco Pharma (Canada) Inc., has invested $8 million in U.S. biotechnology company eGenesis, Inc.
“We are delighted to partner with eGenesis, Inc. for their pioneering work in the field of xenotransplantation. We share eGenesis’ vision that xenotransplantation technology has the potential to end the global transplant shortage and transform the treatment of organ failure by eliminating waitlist mortality,” said Rajeev Nannapaneni, vice president and general manager of Natco Pharma, in a statement.
“We are delighted to welcome Natco as an investor. Their support will help us advance our research and bring our innovative therapies to market,” said Mike Curtis, CEO of eGenesis.
In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was approved by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.
genomic engineering
eGenesis is pioneering a genome engineering-based approach to developing safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure.
The eGenesis Genome Engineering and Manufacturing (EGEN) platform is the only technology of its kind to comprehensively address inter-species molecular incompatibilities and viral risk through genetic engineering to improve the lives of patients in need of transplantation.
Based in Cambridge, eGenesis is focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.
